Developmental toxicity of the anthraquinone dye alizarin to zebrafish: Effects on development and behaviour

Read full text
Authors: Justin Dubiel, Luis Terrazas-Salgado, Natália Oliveira de Farias, Lauren Zink, Rayen Morales Urrutia, Cameron H. Collins, Lauren Eagon, Laura Pizarro, Manos Vogiatzakis, Carter Langevin, Jon A. Doering, Gisela de Aragão Umbuzeiro
+1 more Steve B. Wiseman
Cited by: 1
References: 66

Abstract

There is a push for development of more ecologically friendly alternatives to synthetic dyes, with the natural anthraquinone dye alizarin (1,2-dihydroxyanthraquionone) representing a promising alternative. However, the toxicity of alizarin is not well characterized. The present study investigated the effects of alizarin on zebrafish ( Danio rerio ) embryos, including potential mechanisms of toxicity. Alizarin caused dose-dependent increases in mortality, developmental malformations, and altered behavioural responses to photokinetic stimuli. Zebrafish exposed to alizarin had increased transcript abundance of genes important for the response to oxidative stress, suggesting oxidative stress contributes to toxicity. Additionally, alizarin activated the aryl hydrocarbon receptor (AhR) in an in vitro AhR transactivation assay, and in vivo , suggesting that the toxicity could be partly AhR mediated. These results highlight a need for further investigation into the AhR-mediated and oxidative stress responses following exposure to alizarin and highlight the potential adverse effects on biota despite being a natural dye. • Exposure to alizarin cause developmental toxicity to early life-stage zebrafish • Exposure to alizarin altered behaviour of larvae • Evidence that alizarin caused oxidative stress in embryos • Alizarin activated the aryl-hydrogen receptor in vitro and in embryos

Fields of Study & Subjects

Zebrafish Biomedical Research Applications Phytochemistry and biological activity of medicinal plants Bioactive Compounds and Antitumor Agents

Publication details

Journal / source
Environmental Toxicology and Pharmacology
Publisher
Elsevier BV
Volume
124
Pages
105014–105014
Publication date
31 March 2026
Language
EN